182 related articles for article (PubMed ID: 29016454)
1. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
Sudhalkar A; Kodjikian L; Chhablani J; Bhojwani D; Vasavada A
Retina; 2018 Dec; 38(12):2343-2349. PubMed ID: 29016454
[TBL] [Abstract][Full Text] [Related]
2. LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY.
Rezkallah A; Mathis T; Abukhashabah A; Voirin N; Malclès A; Agard É; Lereuil T; Denis P; Dot C; Kodjikian L
Retina; 2021 Jul; 41(7):1438-1445. PubMed ID: 33315814
[TBL] [Abstract][Full Text] [Related]
3. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.
Malclès A; Dot C; Voirin N; Vié AL; Agard É; Bellocq D; Denis P; Kodjikian L
Retina; 2017 Jul; 37(7):1352-1359. PubMed ID: 27768641
[TBL] [Abstract][Full Text] [Related]
4. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.
Choi W; Park SE; Kang HG; Byeon SH; Kim SS; Koh HJ; Lee S; Seong GJ; Kim CY; Kim M
Br J Ophthalmol; 2019 Oct; 103(10):1380-1387. PubMed ID: 30523044
[TBL] [Abstract][Full Text] [Related]
5. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
[TBL] [Abstract][Full Text] [Related]
6. OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
Chin EK; Almeida DRP; Velez G; Xu K; Peraire M; Corbella M; Elshatory YM; Kwon YH; Gehrs KM; Boldt HC; Sohn EH; Russell SR; Folk JC; Mahajan VB
Retina; 2017 Jul; 37(7):1345-1351. PubMed ID: 27806001
[TBL] [Abstract][Full Text] [Related]
7. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
Reid GA; Sahota DS; Sarhan M
Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
[TBL] [Abstract][Full Text] [Related]
8. Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: a Zambian perspective.
Raj P; Kumar K; Balasubramaniam S; Geetha CS; Agarwal A
Pan Afr Med J; 2021; 39():108. PubMed ID: 34512844
[TBL] [Abstract][Full Text] [Related]
9. Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg Triamcinolone.
Kuley B; Storey PP; Pancholy M; Obeid A; Murphy J; Goodman J; Wibbelsman TD; Regillo C; Chiang A
Semin Ophthalmol; 2020 Feb; 35(2):141-146. PubMed ID: 32343619
[No Abstract] [Full Text] [Related]
10. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema.
Mazzarella S; Mateo C; Freixes S; Burés-Jelstrup A; Rios J; Navarro R; García-Arumí J; Corcóstegui B; Arrondo E
Ophthalmic Res; 2015; 54(3):143-9. PubMed ID: 26394206
[TBL] [Abstract][Full Text] [Related]
11. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis.
Pelegrín L; de la Maza MS; Molins B; Ríos J; Adán A
Eye (Lond); 2015 Jul; 29(7):943-50. PubMed ID: 25998942
[TBL] [Abstract][Full Text] [Related]
12. Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice.
Hemarat K; Kemmer JD; Porco TC; Eaton AM; Khurana RN; Stewart JM
Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):680-685. PubMed ID: 30222802
[TBL] [Abstract][Full Text] [Related]
13. [Late steroid-induced ocular hypertension after intravitreal dexamethasone implants: A series of 20 cases].
Billant J; Douma I; Agard E; Levron A; Bouvarel H; Leroux P; Badri Y; Dot C
J Fr Ophtalmol; 2023 Nov; 46(9):1039-1046. PubMed ID: 37758545
[TBL] [Abstract][Full Text] [Related]
14. XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases.
Rezkallah A; Mathis T; Denis P; Kodjikian L
J Glaucoma; 2019 Jan; 28(1):e5-e9. PubMed ID: 30234749
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients.
Adán A; Pelegrín L; Rey A; Llorenç V; Mesquida M; Molins B; Ríos J; Keller J
Retina; 2013; 33(7):1435-40. PubMed ID: 23514796
[TBL] [Abstract][Full Text] [Related]
16. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis.
Tomkins-Netzer O; Taylor SR; Bar A; Lula A; Yaganti S; Talat L; Lightman S
Ophthalmology; 2014 Aug; 121(8):1649-54. PubMed ID: 24650556
[TBL] [Abstract][Full Text] [Related]
17. INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.
Maturi RK; Pollack A; Uy HS; Varano M; Gomes AM; Li XY; Cui H; Lou J; Hashad Y; Whitcup SM;
Retina; 2016 Jun; 36(6):1143-52. PubMed ID: 26871523
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience.
Monsellato R; Trovato E; Turchetti P; Forestiere M; Pistone A; De Sio S; Accetta L; Pacella F
Clin Ter; 2020; 170(1):e11-e14. PubMed ID: 31850478
[TBL] [Abstract][Full Text] [Related]
19. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors.
Rezkallah A; Kodjikian L; Malclès A; Dot C
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):219-220. PubMed ID: 28801709
[No Abstract] [Full Text] [Related]
20. EFFICACY AND SAFETY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR PERSISTENT UVEITIC CYSTOID MACULAR EDEMA.
Khurana RN; Porco TC
Retina; 2015 Aug; 35(8):1640-6. PubMed ID: 25741813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
